Table 3.

Strategies to Isolate SARS-CoV-2 Neutralizing Antibodies

Ab Source	Clone	Target	Type of Antibody	Neutralization	Inhibition of ACE2/RBD Binding	Reference
Derived from COVID-19 patients	31B532D4	RBD	human monoclonal	yes	yes	Chen et al., 2020a
	P2C-2F6P2C-1F11	RBD	human monoclonal	yes	yes	Ju et al., 2020
Derived from SARS-CoV-1 patients	CR3022	RBD	human monoclonal	no	no	Tian et al., 2020b, Yuan et al., 2020, Giron et al., 2020
	S309	RBD	human monoclonal	yes	no	Pinto et al., 2020
Derived from SARS-CoV-1 or MERS-CoV-1 animal models	R325R302R007	S1	rabbit monoclonal	yes	no	Sun et al., 2020
	47D11	S1	recombinant human monoclonal (derived from hybridomas of immunized transgenic H2L2 mice)	yes	no	Wang et al., 2020a
	VHH-72-Fc	S	Fc-fusion derived from camelids VHH	yes	yes	Wrapp et al., 2020
		S	polyclonal mouse antibodies	yes	N/A	Walls et al., 2020, Yuan et al., 2020
Other	ACE2-Fc	RBD	ACE2-Fc fusion	yes	N/A	Lei et al., 2020a, Li et al., 2020d
	RBD-Fc	ACE2	RBD-Fc fusion	yes	N/A	Li et al., 2020d
	N3130	S1	human monoclonal single domain antibody isolated by phage display	yes	no	Wu et al., 2020c
	IVIg	N/A	polyclonal human IVIg	N/A	N/A	Díez et al., 2020, Shao et al., 2020
	F(ab′)2	RBD	horse polyclonal	yes	N/A	Pan et al., 2020

N/A, not assessed.